UK MHRA Draws Up A Roadmap Of Patient Protection And Rapid Science Uptake
Executive Summary
The UK's health care products regulator wants to capitalize on its post-EU, standalone status by setting an agenda for change that protects public health through excellence in regulation and science.
You may also be interested in...
UKCA Marking Debate Moves To Next Level: All Eyes On The MHRA
The MHRA is under pressure to deliver a new sovereign devices regulatory system in the tightest of timelines for the post-Brexit UK market. It has had no lack of support in this endeavor from system users, but industry is now keen to see the regulator deliver on its two-year plan issued in 2021, says the ABHI’s Phil Brown, in this first part of a two-part industry view of future UK needs.
UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
MHRA Chairman Lightfoot Ready To Lead Post-EU Agenda For UK Devices
The UK devices regulator will prioritize innovation, global best practice and enhanced patient safety and the patient voice, MHRA board chairman Stephen Lightfoot said during the ABHI’s spring regulatory conference. New fees for industry are also on the cards.